Licensing deal for Coniel
By Gong Si |
October 23, 2013, Wednesday
|
Print Edition
Print Edition
Bristol-Myers Squibb Company yesterday said it has entered into a licensing agreement with Kyowa Hakko Kirin Co Ltd for the exclusive rights in China to commercialize Coniel, a calcium channel blocker for the treatment of hypertension and angina pectoris. This is the first China-specific in-licensing transaction under the company’s business development strategy in China, and an example of the company’s long-term commitment to its presence in China. Coniel was previously marketed in China by Kyowa Hakko Kirin. Additional details of the agreement were not disclosed.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
